Quince Therapeutics Amends 8-K to Clarify Positive LAM-001 Phase 2a Efficacy Data
QNCX sits 28% above its 52-week low of $0.79 on elevated volume (3.8× avg).
Summary
Quince Therapeutics filed an amended 8-K to correct and clarify positive Phase 2a clinical trial results for its newly acquired drug, LAM-001, confirming significant reductions in pulmonary vascular resistance.
Key Events · Product Development and Regulatory · QNCX
-
Material Data Correction
The company amended its May 18, 2026 8-K to correct the reported percentage changes in Pulmonary Vascular Resistance (PVR) for LAM-001 Phase 2a data.
-
Clarification of Positive Efficacy
The correction changes "35.3%" and "28.1%" to "-35.3%" and "-28.1%", respectively, confirming that LAM-001 achieved significant PVR reductions, a positive clinical outcome for pulmonary hypertension.
-
Reinforces Drug Pipeline Value
This clarification reinforces the positive efficacy of LAM-001, a key asset acquired through Orphai Therapeutics, which is important for the company's pipeline given recent challenges.
Analysis · QNCX · Life Sciences
This amendment clarifies previously reported Phase 2a clinical trial data for LAM-001, a drug acquired through Orphai Therapeutics. The correction changes positive percentage changes in Pulmonary Vascular Resistance (PVR) to negative, confirming that the drug achieved significant PVR reductions. This is a crucial clarification, as PVR reduction indicates positive efficacy in treating pulmonary hypertension, reinforcing the drug's potential and the value of the recent acquisition.
At the time of this filing, QNCX was trading at $1.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.2M. The 52-week trading range was $0.79 to $45.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.